Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.

Sec. Hypertension

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1579930

Neutrophil-Lymphocyte Ratio and subclinical atherosclerosis in essential hypertensive patients

Provisionally accepted
  • Sapienza University of Rome, Rome, Italy

The final, formatted version of the article will be published soon.

ABSTRACT Objectives: arterial hypertension plays significant role in promoting the development of organ damage and atherosclerosis; Neutrophil-Lymphocyte Ratio (NLR) is an accessible and cost-effective biomarker, strongly associated to adverse outcomes in patients with coronary artery disease and chronic heart failure. The aim of study was to evaluate the clinical utility of NLR as surrogate of subclinical atherosclerotic damage in patients with essential hypertension. Methods: From January 2024 to November 2024, we have consecutively enrolled 346 patients with essential hypertension. In all patients we have evaluated history, anthropometric data, biochemicals analysis and subclinical organ damage with 24-h urinary excretion of µ-albuminuria, carotid intima-media thickness, transthoracic echocardiography. We have excluded patients with arterial hypertension, coronary artery disease, cerebrovascular or peripheral artery diseases. Results: in our study, we found that patients with higher NLR was related with high blood pressure values, the assumption of more than 3 anti-hypertensive drugs, high prevalence of dyslipidemia and obstructive sleep apnea syndrome. Moreover, NLR values were correlated to higher prevalence of subclinical organ damage (left cardiac ventricular mass, carotid atherosclerosis and higher µ-albuminuria values). Conclusions: our study shows that in essential hypertensive patients, the NLR is significantly correlated with some cardiovascular comorbidities and subclinical organ damage.

Keywords: Neutrophil-lymphocyte ratio, Essential arterial hypertension, Subclinical organ damage, Immune system, organ damage

Received: 19 Feb 2025; Accepted: 07 Oct 2025.

Copyright: © 2025 Petramala, Circosta, Cremonesi, Menichelli, Cimò, Servello, Anastasi, Marino and Letizia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Luca Marino, luca.marino@uniroma1.it

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.